Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2025)

Prelude Therapeutics' EBITDA Margin history spans 2 years, with the latest figure at 303.42% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 75705.0% year-over-year to 303.42%; the TTM value through Dec 2025 reached 1531.15%, up 28829.0%, while the annual FY2025 figure was 819.81%, 99963.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 303.42% at Prelude Therapeutics, up from 721.58% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 303.42% in Q3 2025 and bottomed at 1060.47% in Q3 2024.